Bone Health

Latest News

gavel and money | Image credit: BillionPhotos.com - stock.adobe.com
Biosimilar Cases to Watch: Prolia/Xgeva and Denosumab Competitors

March 11th 2025

The denosumab biosimilar market is poised for disruption with 3 FDA-approved biosimilars, at least 5 awaiting approval, and launches anticipated to start in May 2025, while ongoing patent litigation continues to shape the competitive landscape.

osteoporosis and denosumab | Image credit: crevis - stock.adobe.com
FDA Approves Third Pair of Denosumab Biosimilars

March 4th 2025

EU flag | Image credit: Ivan - stock.adobe.com
EC Approves Celltrion Denosumab, Aflibercept Biosimilars

February 20th 2025

bone fracture | Image credit: eddows - stock.adobe.com
FDA, EMA Approve Second Pair of Denosumab Biosimilars

February 17th 2025

Osteoporosis. | Image Credit: mat - stock.adobe.com
Teriparatide Biosimilar Shows Comparable Efficacy to Reference Drug in Postmenopausal Osteoporosis

February 17th 2025

Podcasts
CFB podcast banner
Latest CME Events & Activities

More News

© 2025 MJH Life Sciences

All rights reserved.